-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Veracyte, Lowers Price Target to $35

Benzinga·11/09/2026 21:20:55
UBS analyst Doug Schenkel maintains Veracyte (NASDAQ:VCYT) with a Buy and lowers the price target from $65 to $35.